TOP TEN perturbations for 40077_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40077_at
Selected probe(set): 207071_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40077_at (207071_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-4.3398333Number of Samples:3 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
T. cruzi study 1 (HMVEC; 24h; bottom) / mock infected cardiac microvascular endothelial cell sample (24h; bottom)
Relative Expression (log2-ratio):-4.206441Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
T. cruzi study 1 (VSMC; 48h) / mock infected vascular smooth muscle cell sample (48h)
Relative Expression (log2-ratio):-3.7542858Number of Samples:3 / 3
| Experimental | T. cruzi study 1 (VSMC; 48h) |
| Human vascular smooth muscle cells (VSMCs) infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 48 hours post infection. Cells were maintained in Ham’s F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. | |
| Control | mock infected vascular smooth muscle cell sample (48h) |
| Human vascular smooth muscle cells (VSMCs) mock-infected and harvested 48 hours post mock infection with 2% FBS medium. Cells were maintained in Ham’s F12K medium with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 10 mM TES, 0.05 mg/ml ascorbic acid, 0.001 mg/ml insulin, 0.01 mg/ml transferrin, 10ng/ml sodium selenite, 0.03 mg/ml endothelial cell growth supplement (ECGS) and 10% FBS. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):3.2548122Number of Samples:7 / 3
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):3.1828842Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
breast cancer study 8 (metastatic) / normal breast tissue
Relative Expression (log2-ratio):-3.130271Number of Samples:2 / 4
| Experimental | breast cancer study 8 (metastatic) |
| Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer. | |
| Control | normal breast tissue |
| Normal human breast samples of healthy female individuals. |
T. cruzi study 1 (HMVEC; 24h; top) / mock infected cardiac microvascular endothelial cell sample (24h; top)
Relative Expression (log2-ratio):-2.898388Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the HMVECs infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by parasite-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; top) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell top, bathed with media from the mock-infected bottom HMVECs, harvested 24 hours post mock infection with 2% FBS medium. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by mock-infected cells in the bottom chamber. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
breast cancer study 15 (inv. dc) / normal breast tissue
Relative Expression (log2-ratio):-2.7591972Number of Samples:5 / 5
| Experimental | breast cancer study 15 (inv. dc) |
| Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery. | |
| Control | normal breast tissue |
| Tissue samples of the breast from healthy female individuals after breast reduction surgery. |
breast cancer study 8 (primary) / normal breast tissue
Relative Expression (log2-ratio):-2.7258787Number of Samples:13 / 4
| Experimental | breast cancer study 8 (primary) |
| Human primary infiltrating ductal carcinoma sample of a female patient with breast cancer. | |
| Control | normal breast tissue |
| Normal human breast samples of healthy female individuals. |
T. cruzi study 1 (BJ; 24h; bottom) / mock infected foreskin fibroblast (BJ) sample (24h; bottom)
Relative Expression (log2-ratio):-2.6475945Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (BJ; 24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. | |
| Control | mock infected foreskin fibroblast (BJ) sample (24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. |